LIPO.US Lipella Pharmaceuticals Inc. Common Stock

Healthcare Biotechnology USA Stocks
0.0006 USD
Close of Nov 14, 2026
0.0002 0.4600
Market cap
USD 2.77K
P/E
-
P/B
0.00x
ROE
-348.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.

Is LIPO.US undervalued?

Graham number

The Graham number of Lipella Pharmaceuticals Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lipella Pharmaceuticals Inc. Common Stock fundamental analysis

No fundamental analysis for Lipella Pharmaceuticals Inc. Common Stock yet.

Lipella Pharmaceuticals Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lipella Pharmaceuticals Inc. Common Stock

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-vers…

Full company profile